A population pharmacokinetic model for sertraline in women during the perinatal period-A contribution from the ConcePTION project.

Monfort, Anaëlle; Cardoso, Evelina; Eap, Chin B; Ansermot, Nicolas; Crettol, Severine; Fischer Fumeaux, Céline J; Graz, Myriam Bickle; Harari, Mathilde Morisod; Weisskopf, Etienne; Gandia, Peggy; Allegaert, Karel; Annaert, Pieter; Nordeng, Hedvig; Hascoët, Jean-Michel; Claris, Olivier; Epiney, Manuella; Ferreira, Ema; Leclair, Grégoire; Csajka, Chantal; Panchaud, Alice; ... (2024). A population pharmacokinetic model for sertraline in women during the perinatal period-A contribution from the ConcePTION project. (In Press). British journal of clinical pharmacology Wiley 10.1111/bcp.16177

Preview

Text Brit_J_Clinical_Pharma_-_2024_-_Monfort_-_A_population_pharmacokinetic_model_for_sertraline_in_women_during_the_perinatal.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (1MB) | Preview

AIMS

Sertraline is frequently prescribed for mental health conditions in both pregnant and breastfeeding women. According to the limited available data, only small amounts of sertraline are transferred into human milk, yet with a large amount of unexplained interindividual variability. This study aimed to develop a population pharmacokinetic (popPK) model to describe the pharmacokinetics of sertraline during the perinatal period and explain interindividual variability.

METHODS

Pregnant women treated with sertraline were enrolled in the multicenter prospective cohort SSRI-Breast Milk study. A popPK model for sertraline maternal plasma and breast milk concentrations was developed and allowed estimating the milk-to-plasma ratio (MPR). An additional fetal compartment allowed cord blood concentrations to be described. Several covariates were tested for significance. Ultimately, model-based simulations allowed infant drug exposure through placenta and breast milk under various conditions to be predicted.

RESULTS

Thirty-eight women treated with sertraline were included in the study and provided 89 maternal plasma, 29 cord blood and 107 breast milk samples. Sertraline clearance was reduced by 42% in CYP2C19 poor metabolizers compared to other phenotypes. Doubling milk fat content increased the MPR by 95%. Simulations suggested a median daily infant dosage of 6.9 μg kg-1 after a 50 mg maternal daily dose, representing 0.95% of the weight-adjusted maternal dose. Median cord blood concentrations could range from 3.29 to 33.23 ng mL-1 after maternal daily doses between 25 and 150 mg.

CONCLUSIONS

Infant exposure to sertraline, influenced by CYP2C19 phenotype and breast milk fat content, remains low, providing reassurance regarding the use of sertraline during pregnancy and breastfeeding.

Interest & Impact

Downloads

0 since deposited on 22 Jul 2024
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item